Private insurers decline to cover Biogens new Alzheimers drug in escalating standoff — report – Endpoints News

As the fall­out con­tin­ues from the FDA’s con­tro­ver­sial ap­proval of Bio­gen’s new Alzheimer’s drug Aduhelm, some in­sur­ers are re­port­ed­ly un­will­ing to cov­er the high costs as­so­ci­at­ed … [+4813 chars]